Clinical trials: Multiple Pregnancy
Overactive Bladder, Pharmacokinetics
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
This study investigates whether YM178 has an effect on the pharmacokinetics of warfarin, to exclude any drug-drug interaction between YM178 and warfarin, and evaluates the safety and tolerability of warfarin alone and combined…
- Trial name
- NCT00856570
- Testing
- warfarin, YM178
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes
This study is to evaluate the pharmacokinetics and pharmacodynamics of bardoxolone methyl in patients with chronic kidney disease and type 2 diabetes.
- Trial name
- NCT01549769
- Testing
- Bardoxolone Methyl
- Volunteers
- 24 people
- Sponsor
- Biogen
Metastatic Renal Cell Carcinoma
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
Randomized, double-blind, 2-arm crossover study comparing tivozanib hydrochloride and sunitinib in subjects with metastatic RCC who have received no prior systemic therapy for Renal Cell Carcinoma (RCC).
- Trial name
- TAURUS (NCT01673386)
- Testing
- Tivozanib, Sunitinib
- Where
- 38 sites in United States, Belgium and 5 more
- Volunteers
- 58 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Ovarian Cancer
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
The purpose of this study is to evaluate the effect of BSI-201 on the objective response rate in platinum-resistant recurrent ovarian cancer patients receiving gemcitabine and carboplatin.
- Trial name
- NCT01033292
- Testing
- BSI-201
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Sanofi
Relapsed Multiple Myeloma, End-stage Renal Disease
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing.
- Trial name
- NCT01949532
- Testing
- Carfilzomib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Amgen
Stage IV Renal Cell Cancer
A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)
This is a Phase 1/2, proof-of-principle clinical study to assess safety and efficacy of a intradermally administered tumor vaccine (MGN1601). The study will be conducted in patients with advanced renal cell carcinoma.
- Trial name
- ASET (NCT01265368)
- Testing
- MGN1601
- Where
- 3 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Mologen AG
Growth Hormone Deficiency, Idiopathic Short Stature
Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature
This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.
- Conditions
- Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
- Trial name
- NCT04798690
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Dong-A ST Co., Ltd.
Ureteral Stone
Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones
A lower ureteral calculus, which measures 5 millimeters and less, may be easily expelled by symptomatic therapy. Actually, it has about a 50% chance of successful expulsion.
- Trial name
- STONE (NCT01533389)
- Testing
- Silodosin
- Where
- 5 sites in South Korea
- Volunteers
- 114 people
- Sponsor
- JW Pharmaceutical
Renal Failure , Chronic, Anemia
A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.
The purpose of this study is to show that giving PROCRIT (Epoetin alfa) every 2 weeks to increase the hemoglobin (Hb) level and then to adjust the PROCRIT (Epoetin alfa) dose every 4 weeks (Q4W) to maintain Hb levels, is safe and…
- Trial name
- NCT00337935
- Testing
- Epoetin Alfa, Standard of care
- Volunteers
- 157 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Pregnant Women
Milk Free From A1-Type β-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
The aim of the study is to compare the effects of conventional Ultra High Temperature (UHT) milk containing both A1 and A2 type β-caseins (CON) with a2 UHT Milk containing A2 type β-casein only (A1PF) on inflammation, tolerance…
- Trial name
- NCT06980376
- Testing
- a2 UHT milk, Conventional UHT Milk
- Where
- 6 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- a2 Milk Company Ltd.
Fallopian Tube Cancer, Peritoneal Neoplasms
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer
The purpose of this project is to see if weekly carboplatin compared with phenoxodiol in combination with weekly carboplatin, is effective against late stage ovarian cancer and to see what, if any, side-effects of treatment may…
- Conditions
- Fallopian Tube Cancer, Peritoneal Neoplasms, Ovarian Cancer
- Trial name
- OVATURE (NCT00382811)
- Testing
- phenoxodiol, carboplatin
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 142 people
- Sponsor
- MEI Pharma, Inc.
Anemia of Chronic Kidney Disease
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal…
- Trial name
- NCT01971164
- Testing
- JTZ-951
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Shionogi Inc.
Renal Impairment
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
- Trial name
- NCT06318676
- Testing
- Mezigdomide
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Kidney Failure, Chronic, Hemodialysis Complication
The Pristine Post-Market Study
This is a prospective, multi-center, single-arm study designed to assess the safety and performance of the Pristine™ Long-Term Hemodialysis Catheter.
- Conditions
- Kidney Failure, Chronic, Hemodialysis Complication, Hemodialysis Catheter Infection, Hemodialysis Access Failure
- Trial name
- NCT05228132
- Testing
- Pristine™ Long-Term Hemodialysis Catheter
- Where
- 6 sites in United States
- Volunteers
- 142 people
- Sponsor
- C. R. Bard
Ovarian Cancer, Breast Cancer
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
This is a two-way crossover bioequivalence study between test and reference product in patients diagnosed with BRCA mutated ovarian cancer, recurrent ovarian cancer or metastatic breast cancer.
- Trial name
- NCT05258747
- Testing
- Olaparib tablets, 150 mg, Lynparza® (olaparib) tablets 150 mg
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Sandoz
Diabetic Nephropathy
A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
The purpose of this study is to evaluate pharmacodynamics, safety, tolerability and pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects with Albuminuria and Moderately Decreased GFR
- Trial name
- NCT01756716
- Testing
- MT-3995 Low, MT-3995 High
- Where
- 50 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 49 people
- Sponsor
- Tanabe Pharma Corporation
Menorrhagia
Registry Study of Genesys HTA for Treatment of Menorrhagia
This is a clinical registry of an FDA approved device system called the Genesys Hydro ThermAblatorTM (HTA) system (Boston Scientific).
- Trial name
- Genesys HTA (NCT01197547)
- Testing
- Genesys HTA
- Where
- 19 sites in United States
- Volunteers
- 1,014 people
- Sponsor
- Minerva Surgical, Inc.
Pelvic Inflammatory Disease
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)
- Trial name
- NCT00453349
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Levofloxacin & Metronidazole
- Where
- 13 sites in China, Indonesia and 5 more
- Volunteers
- 460 people
- Sponsor
- Bayer
HSIL of Cervix, HSIL, High Grade Squamous Intraepithelial Lesions
Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.
This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.
- Conditions
- HSIL of Cervix, HSIL, High Grade Squamous Intraepithelial Lesions, High-Grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus
- Trial name
- NCT03697226
- Testing
- Topical ABI-1968
- Where
- South Africa
- Volunteers
- 8 people
- Sponsor
- Antiva Biosciences
Bladder Cancer
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
This is an integrated Phase 1, single centre, 2-part, open-label, dose-escalation study conducted in healthy volunteers to assess the safety, tolerability, and PK of APL-1501 ER capsules in comparison to APL-1202 IR tablets.
- Trial name
- NCT06034015
- Testing
- APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose)
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.